NovoHeart Files Patent Application on Three-Tier Drug Screening System

Novoheart (TSXV:NVH) announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO for a three-tiered drug screening system with enhanced capability, sensitivity and accuracy for detecting pharmacological effects on heart contractility that cannot be achieved with conventional models.
As quoted in the press release:

Owing to the lack of reliable human heart models, drug development is a notoriously lengthy, expensive and inefficient process, plagued with false negative and false positive results which lead to unacceptably high failure rates of >90%. The ability to reliably detect cardiac efficacy and toxicity early on during drug development is crucial for success; yet currently available tools are inadequate in terms of their accuracy and sensitivity.
To answer the unmet demand, the Company developed its proprietary drug screening system which comprises two types of bioengineered tissue constructs from Novoheart’s MyHeart™ Platform, utilized in a tiered fashion: the first stage of screening utilizes the human ventricular cardiac tissue strip (hvCTS) for identifying effects in larger numbers of drug candidates, followed by verification in the second stage using the sophisticated human ventricular cardiac organoid chamber (hvCOC, or “human heart-in-a-jar™”), an exclusive Novoheart technology whose three-dimensional architecture and best-in-class physiological readouts allow highly sensitive detection to avoid false negatives and positives.

Click here to read the full press release.